Confluent (NASDAQ:CFLT – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at William Blair in a ...

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (NasdaqGS:INCY) from Outperform to Market Perform. Analyst Price Forecast Suggests 28.39% Upside As of March 4, ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Incyte (NASDAQ:INCY – Free Report) had its price target reduced by Truist Financial from $74.00 to $72.00 in a report issued on Tuesday,Benzinga reports. They currently have a hold rating on the ...

Overall, Palantir has had a solid start to 2025. Its growth numbers look impressive, and its AI platform is gaining traction across industries. Yet not everyone is convinced. Some ...

Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.

The preppies of 2025 have shown off their best smile and posed for our annual feature on young Townsvillians starting school ...